SCHEMBL378434

SCHEMBL378434

CN(C)C1CCC[N]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL933624 0.92
SCHEMBL4178499 0.90 ADH1C (0.30)
SCHEMBL4162252 0.90 ADH1C (0.30)
SCHEMBL2782050 0.85
SCHEMBL4723746 0.75
SCHEMBL4723756 0.72 ADH1C (0.31)
SCHEMBL4635557 0.72
SCHEMBL4720323 0.69
SCHEMBL4722161 0.69 NOS3 (0.34)
SCHEMBL4720127 0.69 ADH1A (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3898639-A1 OXOPYRIDO[1,2-A]PYRIMIDINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2021-10-27 EP claimed
US-20210317141-A1 OXOPYRIDO[1,2-A]PYRIMIDINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION HOFFMANN-LA ROCHE INC. (US) 2021-10-14 US claimed
US-20210253575-A1 PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN-LA ROCHE INC. (US) 2021-08-19 US claimed
CN-113195503-A Oxopyrido [1,2-A ] pyrimidine compounds for the treatment and prevention of bacterial infections 豪夫迈·罗氏有限公司 2021-07-30 CN claimed
CN-113164418-A Combination therapy 米拉蒂治疗股份有限公司 2021-07-23 CN claimed
EP-3601282-B1 NOVEL PYRIDO[2,3-B]INDOLE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION HOFFMANN LA ROCHE (CH) 2021-07-21 EP claimed
EP-3847165-A1 NOVEL PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2021-07-14 EP claimed
CN-112955137-A Combination therapy 米拉蒂治疗股份有限公司 2021-06-11 CN claimed
CN-111989321-A KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2020-11-24 CN claimed
US-20200339603-A1 Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection HOFFMANN-LA ROCHE INC. (US) 2020-10-29 US claimed
US-20040092521-A1 Bicyclic-substituted amines as histamine-3 receptor ligands ABBOTT LABORATORIES 2004-05-13 US claimed
EP-1370546-A2 NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS Abbott Laboratories (US) 2003-12-17 EP claimed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US claimed
WO-2003027102-A1 3-(ARYLAMINO)METHYLENE-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-04-03 WO claimed
WO-2002074758-A2 NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LABORATORIES (US) 2002-09-26 WO claimed
EP-0160284-B1 QUINO-BENOXAZINE ANTIBACTERIAL COMPOUNDS ABBOTT LABORATORIES (US) 1990-10-24 EP claimed
EP-0162333-B1 QUINO-BENZOTHIAZINE ANTIBACTERIAL COMPOUNDS ABBOTT LABORATORIES (US) 1990-06-27 EP claimed
US-4607032-A Quino-benoxazine antibacterial compounds ABBOTT LABORATORIES (US) 1986-08-19 US claimed
EP-0162333-A1 Quino-benzothiazine antibacterial compounds ABBOTT LABORATORIES (US) 1985-11-27 EP claimed
EP-0160284-A1 Quino-benoxazine antibacterial compounds ABBOTT LABORATORIES (US) 1985-11-06 EP claimed